A game-changer for chronic

Wound
Treatment

Achieve total and faster wound healing with AUP-16, a topical cell therapy that accelerates healing of diabetic foot ulcers and other chronic, non-healing wounds.

Chronic and non-healing wound treatment is

Complex

Many available products can treat symptoms or target limited steps in the wound healing pathway: traditional or moist wound dressings, negative pressure wound therapy, cell and tissue based products, skin substitutes, growth factors.... Aurealis Therapeutics’ four-in-one topical treatment, AUP-16, accelerates healing by targeting multiple wound healing pathways and promoting tissue regeneration. Our unique technology overcomes the limitations of combining current treatments or combining existing therapeutic protein treatments, replacing them with a single therapeutic agent.

AUP-16:

One medicine has the benefits of four therapeutics

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.

AUP for treatment of diabetic foot ulcer

This novel therapeutic is backed by pre-clinical and clinical results in wide-ranging applications like diabetic foot ulcers, other non-healing wounds, and inflammatory diseases. AUP-16 is made from live, food-grade bacteria and has the power to accelerate and provide complete wound healing, making future amputations unnecessary.

This remarkable advancement is ideal for patients who only achieve partial response to wound care dressings and treatment of symptoms. As opposed to the existing standard of care, AUP-16 promotes tissue regeneration in the wound to activate healing from within.

Highlights of AUP-16

Four-in-one

cell therapy stimulates
endogenous
tissue regeneration

Bioavailable

protein production
at the site of injury

Topical Application

makes it easy to
adminsiter

Safe

modified food-
grade bacteria

Learn more

About this
life-changing
technology

For Investors and Strategic Partners

Contact us

News Feed

Aurealis Therapeutics Publishes First Study on Four-in-One -Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds

Basel Switzerland and Kuopio Finland– March 1st, 2022.  Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This … Aurealis Therapeutics Publishes First...

Read

Aurealis Therapeutics to Strengthen Its Management Team by Appointing Dr. Laurent Décory as Chief Operating Officer

Basel Switzerland and Kuopio Finland– February 25th, 2022. Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business … Aurealis Therapeutics to Strengthen...

Read

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Basel Switzerland, Kuopio Finland, and Shenzhen China – January 28th, 2022. Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis … Aurealis Therapeutics and Xbiome...

Read